---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-011839"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-24T23:44:59.299313+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ovid Therapeutics Q4/FY2024 net loss $26.4M; cash into H2 2026; OV329 data Q3 2025

## Summary
- Net loss $26.4M ($0.37/diluted) for FY2024 vs $52.3M in 2023; royalty revenue $566K.
- Cash & securities $53.1M expected to fund operations into H2 2026.
- Topline Phase 1 results for OV329 (GABA-AT inhibitor) expected Q3 2025; no SAEs to date.
- OV350 (first KCC2 direct activator) began Phase 1 in Q1 2025; topline data expected Q4 2025.
- Stelios Papadopoulos appointed to Board; Manal Morsy (Chief Regulatory Officer) and Victoria Fort (Corporate Affairs) joined.

## SEC filing metadata
- accession: 0001628280-25-011839
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000162828025011839/0001628280-25-011839-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000162828025011839/ovid-20250311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-011839
- JSON: https://secwatch.observer/filing/0001628280-25-011839.json
- Plain text: https://secwatch.observer/filing/0001628280-25-011839.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.